Adviser is a patent-pending cloud computing platform that makes it easy for anyone to run computational, AI, & data science workloads in the cloud.
80% of all business data is structured data in the form of tables and databases but regulatory constraints like HIPAA, CCPA & GDPR make it difficult and costly for enterprise data-teams working regulated data. dbTwin is a enterprise platform that unlocks secure, data-driven innovation in sectors like healthcare, finance and tech by letting data-teams create private but realistic versions of their databases critical for training AI models, prototyping analytics workflows and functional testing of software/products.
CHALK is an easy-to-use classroom observation and professional development platform for early learning and kindergarten classrooms.
Augment Health is developing a noninvasive bladder monitor and AI algorithm for 7M patients with bladder dysfunction following neurologic disease or injury, a $10.2B market.
Imagine Devices develops Trinity Tube, the first multifunctional neonatal feeding tube that integrates feeding, vital signs, and respiratory monitoring into a single device.
This innovative solution improves safety, reduces clinical workload, and enhances care for premature infants in NICUs worldwide.
Corvivo Cardiovascular is a commercial-stage regenerative medical device company focused on cardiovascular repair and regeneration products.
Its flagship Natev™ Tricuspid Valve is a regenerative valve for surgical management of tricuspid valve disease, damage, and dysfunction in adult and pediatric patients—now in final stages of FDA review.
iNOvodel is a medical technology company commercializing a novel system for delivering inhaled nitric oxide (iNO) therapy.
Our proprietary platform generates highly concentrated iNO using safe, low-cost chemicals and rapidly mixes it to minimize harmful NO₂ formation—offering improved safety, portability, ease of use, and lower cost compared to existing hospital-based systems.
iNOvodel aims to expand iNO therapy to broader patient populations and new clinical settings.
